194 related articles for article (PubMed ID: 29533022)
1. Endometrial cancer risk and survival by tumor MMR status.
Nagle CM; O'Mara TA; Tan Y; Buchanan DD; Obermair A; Blomfield P; Quinn MA; Webb PM; Spurdle AB;
J Gynecol Oncol; 2018 May; 29(3):e39. PubMed ID: 29533022
[TBL] [Abstract][Full Text] [Related]
2. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities.
Garg K; Leitao MM; Kauff ND; Hansen J; Kosarin K; Shia J; Soslow RA
Am J Surg Pathol; 2009 Jun; 33(6):925-33. PubMed ID: 19238076
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
[TBL] [Abstract][Full Text] [Related]
4. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
5. Does MMR status in endometrial cancer influence response to adjuvant therapy?
Kim SR; Pina A; Albert A; McAlpine J; Wolber R; Blake Gilks C; Kwon JS
Gynecol Oncol; 2018 Oct; 151(1):76-81. PubMed ID: 30172479
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
Yoneoka Y; Yoshida H; Ishikawa M; Shimizu H; Uehara T; Murakami T; Kato T
J Gynecol Oncol; 2019 Jan; 30(1):e7. PubMed ID: 30479091
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
McMeekin DS; Tritchler DL; Cohn DE; Mutch DG; Lankes HA; Geller MA; Powell MA; Backes FJ; Landrum LM; Zaino R; Broaddus RD; Ramirez N; Gao F; Ali S; Darcy KM; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
J Clin Oncol; 2016 Sep; 34(25):3062-8. PubMed ID: 27325856
[TBL] [Abstract][Full Text] [Related]
9. Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch-associated cancers-A population-based analysis.
Johnatty SE; Stewart CJR; Smith D; Buchanan D; Leung Y; Oehler MK; Brand A; Webb PM; Spurdle AB
Cancer Med; 2018 Dec; 7(12):6411-6422. PubMed ID: 30485707
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis.
Diaz-Padilla I; Romero N; Amir E; Matias-Guiu X; Vilar E; Muggia F; Garcia-Donas J
Crit Rev Oncol Hematol; 2013 Oct; 88(1):154-67. PubMed ID: 23562498
[TBL] [Abstract][Full Text] [Related]
11. Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
Ta RM; Hecht JL; Lin DI
Gynecol Oncol; 2018 Dec; 151(3):401-406. PubMed ID: 30340772
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers.
Kim SR; Pina A; Albert A; McAlpine JN; Wolber R; Gilks B; Carey MS; Kwon JS
Int J Gynecol Cancer; 2020 Jun; 30(6):783-788. PubMed ID: 32354793
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas.
Shikama A; Minaguchi T; Matsumoto K; Akiyama-Abe A; Nakamura Y; Michikami H; Nakao S; Sakurai M; Ochi H; Onuki M; Satoh T; Oki A; Yoshikawa H
Gynecol Oncol; 2016 Feb; 140(2):226-33. PubMed ID: 26644264
[TBL] [Abstract][Full Text] [Related]
15. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair status and surgical approach in apparent early-stage endometrial cancer.
Morton R; Webb PM; Na R; Obermair A; Farrell R
Int J Gynecol Cancer; 2024 Apr; 34(4):535-543. PubMed ID: 38431289
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
18. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas.
McConechy MK; Talhouk A; Li-Chang HH; Leung S; Huntsman DG; Gilks CB; McAlpine JN
Gynecol Oncol; 2015 May; 137(2):306-10. PubMed ID: 25636458
[TBL] [Abstract][Full Text] [Related]
19. Sporadic endometrial adenocarcinoma with MMR deficiency due to biallelic MSH2 somatic mutations.
Buecher B; De Pauw A; Bazire L; Houdayer C; Fievet A; Moncoutier V; Farkhondeh F; Melaabi S; Lyonnet DS; Golmard L
Fam Cancer; 2018 Apr; 17(2):281-285. PubMed ID: 28819700
[TBL] [Abstract][Full Text] [Related]
20. Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Vagios S; Doulgeraki T; Giannikaki E; Kavoura E; Papadimitriou C; Gakiopoulou H; Pavlakis K
Anticancer Res; 2020 Mar; 40(3):1669-1676. PubMed ID: 32132073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]